Cancer BiologybioRxiv
Multiple Myeloma: Combination Therapy of BET Proteolysis Targeting Chimeric Molecule with CDK9 Inhibitor
S. L. Lim, P. Koeffler, L. Xu…·W. J. Chng
This study shows that combining a BET PROTAC (ARV 825) with a CDK9 inhibitor (AZD 4573) effectively reduces multiple myeloma cell viability and induces apoptosis.
DOI 10.1371/journal.pone.0232068